Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
109.75
+3.98 (3.76%)
Jun 11, 2026, 3:25 PM EDT - Market open
Protagonist Therapeutics Revenue
Protagonist Therapeutics had revenue of $56.37M in the quarter ending March 31, 2026, with 99.03% growth. This brings the company's revenue in the last twelve months to $74.06M, down -64.36% year-over-year. In the year 2025, Protagonist Therapeutics had annual revenue of $46.02M, down -89.41%.
Revenue (ttm)
$74.06M
Revenue Growth
-64.36%
P/S Ratio
91.84
Revenue / Employee
$565,366
Employees
131
Market Cap
7.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.02M | -388.42M | -89.41% |
| Dec 31, 2024 | 434.43M | 374.43M | 624.06% |
| Dec 31, 2023 | 60.00M | 33.42M | 125.73% |
| Dec 31, 2022 | 26.58M | -776.00K | -2.84% |
| Dec 31, 2021 | 27.36M | -1.27M | -4.44% |
| Dec 31, 2020 | 28.63M | 28.40M | 12,293.07% |
| Dec 31, 2019 | 231.00K | -30.69M | -99.25% |
| Dec 31, 2018 | 30.93M | 10.86M | 54.14% |
| Dec 31, 2017 | 20.06M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.14B |
| PTC Therapeutics | 827.11M |
| TG Therapeutics | 700.35M |
| Mirum Pharmaceuticals | 569.61M |
| Rhythm Pharmaceuticals | 217.17M |
| Kymera Therapeutics | 51.48M |
| Centessa Pharmaceuticals | 15.00M |
PTGX News
- 1 day ago - Protagonist Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 8 days ago - Protagonist Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 10 days ago - Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress - Accesswire
- 10 days ago - Protagonist Therapeutics Slides: Company presentation - Filings
- 14 days ago - Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026 - Accesswire
- 4 weeks ago - Protagonist Therapeutics price target raised to $130 from $125 at Citi - TheFly
- 5 weeks ago - Protagonist Therapeutics price target raised to $137 from $120 at Citizens - TheFly
- 5 weeks ago - Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs - TheFly